Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes - Wikidata - awgldk - TriplyDB

Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes

Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes

http://www.wikidata.org/entity/Q27689597

about

Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes DPP4 in Diabetes Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.Modeling & Informatics at Vertex Pharmaceuticals Incorporated: our philosophy for sustained impact.Comprehensive analysis of the Co-structures of dipeptidyl peptidase IV and its inhibitor A Thorough QTc Study Confirms Early Pharmacokinetics/QTc Modeling: A Supratherapeutic Dose of Omarigliptin, a Once-Weekly DPP-4 Inhibitor, Does Not Prolong the QTc Interval.Sensitive and specific LC-ESI-MS/MS method for determination of ZYDPLA1, a novel long-acting dipeptidyl peptidase 4 inhibitor in rat plasma: An application for toxicokinetic study in rats.Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlle The Current Drug Treatment Landscape for Diabetes and Perspectives for the Future.Omarigliptin: first global approval.First novel once-weekly DPP-4 inhibitor, trelagliptin, for the treatment of type 2 diabetes mellitus.Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas.Investigational insulin secretagogues for type 2 diabetes.Omarigliptin for the treatment of type 2 diabetes.Omarigliptin for the treatment of type 2 diabetes mellitus.Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis.Effects of Age, Sex, and Obesity on the Single-Dose Pharmacokinetics of Omarigliptin in Healthy Subjects.Single and multiple dose pharmacokinetics and pharmacodynamics of omarigliptin, a novel, once-weekly dipeptidyl peptidase-4 inhibitor, in healthy Japanese men A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control.A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus.Finding a Potential Dipeptidyl Peptidase-4 (DPP-4) Inhibitor for Type-2 Diabetes Treatment Based on Molecular Docking, Pharmacophore Generation, and Molecular Dynamics Simulation.Discovery of Novel Tricyclic Heterocycles as Potent and Selective DPP-4 Inhibitors for the Treatment of Type 2 Diabetes.RETRACTED: Therapeutic stimulation of GLP-1 and GIP protein with DPP-4 inhibitors for type-2 diabetes treatment.Pharmacokinetics and Pharmacodynamics of Omarigliptin, a Once-Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitor, After Single and Multiple Doses in Healthy Subjects.Efficacy and Patient Satisfaction of the Weekly DPP-4 Inhibitors Trelagliptin and Omarigliptin in 80 Japanese Patients with Type 2 Diabetes.Synthesis of New DPP-4 Inhibitors Based on a Novel Tricyclic Scaffold.A randomized, placebo- and sitagliptin-controlled trial of the safety and efficacy of omarigliptin, a once-weekly dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes.Pharmacological characterization of ZYDPLA1, a novel long-acting dipeptidyl peptidase-4 inhibitor.A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin.Ultra-high pressure liquid chromatography-tandem mass spectrometry method for the determination of omarigliptin in rat plasma and its application to a pharmacokinetic study in rats.A randomised, double-blind, trial of the safety and efficacy of omarigliptin (a once-weekly DPP-4 inhibitor) in subjects with type 2 diabetes and renal impairment.Asymmetric Formal Synthesis of the Long-Acting DPP-4 Inhibitor Omarigliptin.Crystal structures of a bacterial dipeptidyl peptidase IV reveal a novel substrate recognition mechanism distinct from that of mammalian orthologues.A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy.Synthesis of [(14) C]omarigliptin.Repositioning of Omarigliptin as a once-weekly intranasal Anti-parkinsonian Agent.

P2860

Q26785454-CD99B048-5724-450D-B475-97828CA797F2 Q26797335-F8A17006-6E5A-40E8-A2BB-9A7EF67F3A81 Q30249371-CB803421-830C-4731-AAB9-44B4AC60CB8C Q30395805-D955958C-57EF-45EC-AFED-26D57CF9CB43 Q36095299-2ADD9162-B255-4741-8C35-5DE3EAAAB47F Q36132590-D8089279-9CE2-45FC-B8C8-28B8584DECEC Q36332490-BF7A3ADD-0E47-4D7E-872F-042174E2F25F Q37696556-3B244A0D-DE10-48AB-837F-C948DEE5B7C7 Q38474070-0B06A633-9116-4F05-A433-BAC33D4845C2 Q38617868-521514DE-48FB-4E71-BD33-22E8D568A857 Q38622203-44A56435-91AB-47B8-BE2D-10AF0958B016 Q38644587-3BAD5734-FDDC-4A1F-B4BF-A279717429DC Q38735419-2A126937-E853-46A3-8637-467D57A7015A Q38884175-99E98EC4-AA4E-4840-B807-56F97038D7A5 Q38910804-82DFD26A-BFD2-45B6-9E35-0682EB0B471E Q39266678-B82EB79F-9DDF-46F4-897D-00EB6392759D Q39391542-2ACBEDA1-783A-48D6-85A0-8C0FB8966134 Q40888889-3B25DEDA-C35D-4A80-986E-23F4252EA023 Q41259354-80266F5C-5224-4277-B67F-3049FDEDE0E1 Q41278816-C05211BE-3E3F-4D16-9DEE-C407A80AFFFE Q41812639-8B89843A-61C5-43D5-A7D1-846EE7E4CB1B Q41888359-BA72BEA4-EF52-454C-A652-FAF49981ED01 Q42105494-7ACA06FC-8313-4315-940F-CFB3605952D6 Q42138923-D28F39A7-8012-4CF6-B406-31A7101B0F35 Q42620088-3AAB3992-FE94-4249-A6FE-7D9F72D4F0F0 Q43186587-790369C4-A819-4763-9237-1DD9EF298218 Q45983099-DD31BF50-CF0C-4379-BB18-90EA5CD66BAE Q46823969-87B9DF65-124F-47DC-8C46-B1C7F9903494 Q47103205-06F7A3A2-4F7C-4913-A7FB-822600542679 Q48106281-812EF4E2-A002-4EFD-BB8C-2BA0F342A4D0 Q48223871-A3BBA913-ECDC-4FC5-9A96-306B3ABB2CC0 Q48292533-011D5BC0-DBB5-47A5-B9A0-147628DE91C9 Q49370855-B359754B-C2C1-4DD8-8D42-9EABA54BE379 Q51265028-CABC7B26-6FB6-4214-97C6-404C9FEEAE1D Q54537648-EFC42ABF-92FC-4933-9017-D99858D05CC7 Q55190915-1CB3E304-50EF-496B-8F57-A09EFC54FF51

P2860

Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes

http://www.wikidata.org/entity/Q27689597

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Omarigliptin (MK-3102): a nove ...... y treatment of type 2 diabetes

@ast

Omarigliptin (MK-3102): a nove ...... y treatment of type 2 diabetes

@en

Omarigliptin (MK-3102): a nove ...... y treatment of type 2 diabetes

@nl

type

label

Omarigliptin (MK-3102): a nove ...... y treatment of type 2 diabetes

@ast

Omarigliptin (MK-3102): a nove ...... y treatment of type 2 diabetes

@en

Omarigliptin (MK-3102): a nove ...... y treatment of type 2 diabetes

@nl

prefLabel

Omarigliptin (MK-3102): a nove ...... y treatment of type 2 diabetes

@ast

Omarigliptin (MK-3102): a nove ...... y treatment of type 2 diabetes

@en

Omarigliptin (MK-3102): a nove ...... y treatment of type 2 diabetes

@nl

P1433

Q27689597-E1BE275A-9B78-414E-A1CA-D1107BBDC53E

P1476

Q27689597-EBF10207-CA09-4E09-AA19-3544B53F6277

P2093

Q27689597-0650E3CD-BF00-4852-925D-CD6780D04890

Q27689597-0B279F9E-6BBB-4F0E-AEDE-70578D179CC4

Q27689597-1CA959AE-8FC9-485F-AB52-2C656922F33B

Q27689597-35895117-E2F6-44BC-B4F7-2813C16BD84C

Q27689597-39FE6EEA-4873-4534-BBAF-624365F78F37

Q27689597-3B3BB067-B890-4E2E-AE6E-F04FBB1AD050

Q27689597-4863D0D0-0CF2-44CD-926A-D5713A5F41D7

Q27689597-4F9AE7D7-6302-4F14-9568-47F99A78408A

Q27689597-4FEB6F00-D90D-4553-978A-5BF9D7909AD4

Q27689597-5487B198-2C5F-4956-BCF7-639663E3F489

P304

Q27689597-5090A3CB-5F2F-485C-BCEE-B2DDB8819928

P31

Q27689597-B6B1C0B3-7F7E-4B55-89A8-EF0234736B75

P3181

Q27689597-18510347-8D98-4807-A9E0-E3DA8457FD3E

P356

Q27689597-4A053717-700A-4769-A803-A89D5869B618

P407

Q27689597-5DAB43BA-8B3D-46A0-8DA8-53E77BD50028

P433

Q27689597-4AE2FF65-2147-4BDE-A4D2-00C4E7EE09A9

P478

Q27689597-F44204AF-D271-4553-AA49-5E1406930E75

P50

Q27689597-DDA19F91-3C95-4744-949D-F3082CAB0062

P577

Q27689597-B113E498-B5AA-48B5-A71F-11D8F25339F5

P5875

Q27689597-3A98ABA9-37C9-4F50-A290-054C183A306C

P698

Q27689597-2A80FAA1-10EC-47D1-AA93-924BDA9B68A7

P921

Q27689597-C368F048-5DE8-4CCB-BEAD-DA5B2DCD52B5

P3181

P356

P1433

Journal of Medicinal Chemistry

P1476

Omarigliptin (MK-3102): a nove ...... y treatment of type 2 diabetes

@en

P2093

Aleksandr Petrov

http://www.w3.org/2001/XMLSchema#string

Ann E Weber

http://www.w3.org/2001/XMLSchema#string

Annette Bak

http://www.w3.org/2001/XMLSchema#string

Bei Zhang

http://www.w3.org/2001/XMLSchema#string

Charles Sewall

http://www.w3.org/2001/XMLSchema#string

Davida Krueger

http://www.w3.org/2001/XMLSchema#string

Dennis Feng

http://www.w3.org/2001/XMLSchema#string

George Doss

http://www.w3.org/2001/XMLSchema#string

George Eiermann

http://www.w3.org/2001/XMLSchema#string

Gino Salituro

http://www.w3.org/2001/XMLSchema#string

P304

3205-12

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

845579

http://www.w3.org/2001/XMLSchema#string

P356

10.1021/JM401992E

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

57

http://www.w3.org/2001/XMLSchema#string

P50

Giovanna Scapin

P577

2014-04-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261066491

http://www.w3.org/2001/XMLSchema#string

P698

24660890

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes